A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN
Myeloid neoplasm (MPN) clones can evolve from acute myeloid leukemia to gain dominance with isocitrate dehydrogenase inhibition. Pro-differentiation agents such as ivosidenib can unmask MPN sequelae.
Indication / Modality
Acute Myleoid Leukemia (AML), Myeloproliferative Neoplasms (MPN)
Goal of Study
Tissue / Organ
Bone Marrow Aspirates
Proof Point Demonstrated